{"id":"quetiapine-drug","safety":{"commonSideEffects":[{"rate":"18-27%","effect":"Somnolence/sedation"},{"rate":"9-16%","effect":"Dry mouth"},{"rate":"10-18%","effect":"Dizziness"},{"rate":"5-23%","effect":"Weight gain"},{"rate":"13-19%","effect":"Headache"},{"rate":"8-10%","effect":"Constipation"},{"rate":"6-17%","effect":"Tachycardia"},{"rate":"7-9%","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors and has activity at other receptors including histamine H1 and adrenergic receptors, contributing to its mood-stabilizing and anxiolytic effects. This multi-receptor profile distinguishes it from typical antipsychotics and provides efficacy across multiple psychiatric conditions.","oneSentence":"Quetiapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:36.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Major depressive disorder (as adjunctive therapy)"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07401836","phase":"NA","title":"Standardized Sleep Bundle for Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"Horizon Health Network","startDate":"2026-03","conditions":"Sleep","enrollment":20},{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04115319","phase":"PHASE3","title":"A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-11-21","conditions":"Schizophrenia","enrollment":305},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":"Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":288},{"nctId":"NCT05590637","phase":"PHASE4","title":"Comparing Antipsychotic Medications in LBD Over Time","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-04-22","conditions":"Parkinson's Disease Psychosis, Dementia With Lewy Bodies","enrollment":94},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT04513912","phase":"PHASE3","title":"A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Depressive Disorder, Major","enrollment":757},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT06333990","phase":"PHASE3","title":"Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)","status":"RECRUITING","sponsor":"Foundation for Advancing Veterans' Health Research","startDate":"2024-07-09","conditions":"Mild Traumatic Brain Injury","enrollment":146},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT06949657","phase":"NA","title":"Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and","status":"TERMINATED","sponsor":"Third People's Hospital, Huzhou City, Zhejiang Province, China","startDate":"2023-10-13","conditions":"Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy","enrollment":78},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT03449472","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Quetiapine","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2018-01-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT03739476","phase":"PHASE3","title":"Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients","status":"TERMINATED","sponsor":"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","startDate":"2019-02-13","conditions":"Postoperative Delirium","enrollment":54},{"nctId":"NCT04338321","phase":"PHASE3","title":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2020-08-21","conditions":"Depressive Disorder, Major","enrollment":676},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT06062953","phase":"PHASE2, PHASE3","title":"Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia","status":"RECRUITING","sponsor":"Lone Baandrup","startDate":"2023-09-18","conditions":"Psychiatric Disorders, Insomnia","enrollment":255},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT04521478","phase":"PHASE2","title":"A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-20","conditions":"Depressive Disorder, Major","enrollment":389},{"nctId":"NCT04950868","phase":"PHASE1","title":"The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verinder Sharma","startDate":"2022-03-18","conditions":"Postpartum Depression","enrollment":22},{"nctId":"NCT02958800","phase":"NA","title":"Deprescribing Antipsychotics in Long-Term Care","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-12","conditions":"Dementia, Behavior","enrollment":6},{"nctId":"NCT01737268","phase":"PHASE3","title":"Long-term Study of FK949E in Elderly Bipolar Disorder Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10-29","conditions":"Bipolar Disorder, Elderly","enrollment":20},{"nctId":"NCT01725308","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-02-07","conditions":"Bipolar Disorder","enrollment":431},{"nctId":"NCT02362412","phase":"PHASE3","title":"Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-02-18","conditions":"Bipolar Depression","enrollment":22},{"nctId":"NCT01725282","phase":"PHASE2","title":"Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-12-14","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT01919008","phase":"PHASE1","title":"Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-03-26","conditions":"Major Depressive Disorder","enrollment":16},{"nctId":"NCT03403790","phase":"","title":"A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2018-01-15","conditions":"Depression, Bipolar Disorder","enrollment":369},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT06546358","phase":"EARLY_PHASE1","title":"Quetiapine Versus Trazadone in Women With Postpartum Depression","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-09","conditions":"Postpartum Depression","enrollment":50},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT02366897","phase":"NA","title":"Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2017-02-21","conditions":"Drug-induced Extrapyramidal Side Effects","enrollment":21},{"nctId":"NCT04524403","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-09-09","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":150},{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT05307003","phase":"","title":"Trazodone vs. Quetiapine for the Treatment of ICU Delirium","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2023-04-01","conditions":"Delirium, Delirium of Mixed Origin, Delirium, Sepsis Associated","enrollment":60},{"nctId":"NCT05085808","phase":"PHASE4","title":"RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)","status":"NOT_YET_RECRUITING","sponsor":"University of Southern California","startDate":"2025-03-01","conditions":"Delirium, Morality, Quality of Life","enrollment":30},{"nctId":"NCT00232336","phase":"PHASE4","title":"Quetiapine for Cocaine Use and Cravings","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2003-10","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":42},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT06200584","phase":"NA","title":"Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics","status":"COMPLETED","sponsor":"Dr Rabia Arshad","startDate":"2021-01-01","conditions":"Antipsychotics and Neuroleptics Toxicity","enrollment":140},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT05690698","phase":"PHASE3","title":"Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2023-04-09","conditions":"Hyperactive Delirium","enrollment":100},{"nctId":"NCT04936126","phase":"PHASE4","title":"Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2021-08-07","conditions":"Treatment Resistant Depression","enrollment":150},{"nctId":"NCT03786614","phase":"NA","title":"Antidepressant Discontinuation in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"University of Louisville","startDate":"2019-06-20","conditions":"Treatment Resistant Depression","enrollment":30},{"nctId":"NCT05840861","phase":"","title":"Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders","status":"UNKNOWN","sponsor":"Central South University","startDate":"2020-11-05","conditions":"Major Depressive Disorder, Bipolar Disorder","enrollment":59},{"nctId":"NCT05793632","phase":"PHASE2","title":"Quetiapine in Prevention of Delirium","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-03-01","conditions":"Delirium","enrollment":90},{"nctId":"NCT05303935","phase":"PHASE2","title":"Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Flinders University","startDate":"2022-05-25","conditions":"Sleep Apnea, Obstructive","enrollment":15},{"nctId":"NCT04728581","phase":"NA","title":"Improving Sleep After TKA Using Mirtazapine and Quetiapine","status":"NOT_YET_RECRUITING","sponsor":"St. Anna Ziekenhuis, Geldrop, Netherlands","startDate":"2024-01-01","conditions":"Osteo Arthritis Knee, Insomnia","enrollment":165},{"nctId":"NCT04280965","phase":"EARLY_PHASE1","title":"Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-02-01","conditions":"Post Traumatic Stress Disorder","enrollment":28},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT05801289","phase":"NA","title":"Quetiapine as Prophylaxis for Delirium in CABG","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-12-04","conditions":"Delirium","enrollment":60},{"nctId":"NCT04513314","phase":"PHASE4","title":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2023-03-28","conditions":"Covid19, Hyperactive Delirium, Pneumonia, Viral","enrollment":""},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03465787","phase":"PHASE3","title":"A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2018-04-09","conditions":"Schizophrenia","enrollment":210},{"nctId":"NCT01858948","phase":"PHASE3","title":"SGA-induced Metabolic Syndrome in Bipolar Youth","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-07","conditions":"Bipolar Youth Treated With Second-generation Antipsychotics","enrollment":19},{"nctId":"NCT05480150","phase":"NA","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-01","conditions":"Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic","enrollment":10000},{"nctId":"NCT03654378","phase":"","title":"Molecular Basis of Altered Drug Metabolism During Pregnancy","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2018-08-01","conditions":"Pregnancy","enrollment":""},{"nctId":"NCT02978534","phase":"","title":"Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-03","conditions":"Bipolar Disorder","enrollment":4},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT02845453","phase":"PHASE4","title":"Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-01-20","conditions":"Substance Use Disorders, Bipolar Disorder, Mood Disorders","enrollment":24},{"nctId":"NCT05240261","phase":"PHASE1","title":"Sleep Disorders in Chronic Kidney Disease Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-05-01","conditions":"Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT05235230","phase":"PHASE1","title":"Partially Replicate Bioequivalence Study of Quetiapine 25 mg in Healthy Volunteers Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2021-05-19","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT05098353","phase":"NA","title":"Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control","status":"UNKNOWN","sponsor":"Federal Stare Budgetary Scientific Institution, Mental Health Research Center","startDate":"2021-04-10","conditions":"Bipolar Affective Disorder","enrollment":30},{"nctId":"NCT04164758","phase":"PHASE2","title":"Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine","status":"TERMINATED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2019-10-23","conditions":"Parkinson's Disease","enrollment":11},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT00149734","phase":"PHASE3","title":"Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2005-01","conditions":"Schizophrenia","enrollment":8},{"nctId":"NCT04898270","phase":"PHASE4","title":"Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2019-12-19","conditions":"Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol","enrollment":30},{"nctId":"NCT00406315","phase":"PHASE4","title":"Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":255},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT03004521","phase":"PHASE4","title":"Lithium Versus Quetiapine in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"King's College London","startDate":"2016-11","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":276},{"nctId":"NCT00159770","phase":"PHASE3","title":"Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-11","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":290},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT00370500","phase":"PHASE4","title":"Quetiapine and the Dopaminergic Epigenetic Control","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2007-04","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT03872596","phase":"PHASE1","title":"Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-03-27","conditions":"Bipolar Disorder, Schizophrenia","enrollment":58},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT01588457","phase":"PHASE4","title":"Sequential Multiple Assignment Treatment for Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-06","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":112},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT00579280","phase":"PHASE4","title":"Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2007-07","conditions":"Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder","enrollment":224},{"nctId":"NCT03572257","phase":"PHASE2, PHASE3","title":"Quetiapine Treatment for Pediatric Delirium","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2019-04-15","conditions":"Delirium","enrollment":""},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2248,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Quetiapine (drug)","genericName":"Quetiapine (drug)","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Major depressive disorder (as adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}